Glow

Research areas

Investigated pathways and mechanisms

GLOW is a commercial combination of three peptides (GHK‑Cu, BPC‑157, TB‑500). There are no supplied primary studies testing the three‑peptide blend as a single intervention. Mechanistic rationale for the blend is inferred from separate preclinical literature for each component: GHK‑Cu is reported to modulate gene expression related to collagen/proteoglycan synthesis, angiogenesis, antioxidant and anti‑inflammatory pathways (doi-02c27699; doi-51cf1b98375fac3d); BPC‑157 is described in animal models to promote cytoprotection, angiogenesis (VEGF‑linked), fibroblast migration and modulation of inflammatory responses (doi-3edf3bd9318f3ad2; doi-e45b177a84e31df8); TB‑500 (a thymosin beta‑4 fragment) is reported to support actin dynamics, cell migration, angiogenesis and anti‑fibrotic effects in preclinical literature (doi-16e6d8ccee8b0df0). These mechanisms are complementary in that each component has been associated (in separate studies) with processes relevant to tissue repair: angiogenesis, cell migration/proliferation, extracellular matrix remodeling, and modulation of inflammation.

Preclinical evidence

All three components have a substantive preclinical literature (in vitro and animal) showing effects on wound healing–relevant endpoints. GHK‑Cu: multiple laboratory and animal reports indicate stimulation of collagen and proteoglycan production, improved fibroblast/keratinocyte function, antioxidant activity, and angiogenesis (doi-02c27699; doi-51cf1b98375fac3d; doi-7197366080c5ca36). BPC‑157: numerous animal studies report cytoprotective and regenerative effects across gastrointestinal, musculoskeletal and neural models, including tendon and liver injury models (doi-3edf3bd9318f3ad2; doi-e45b177a84e31df8), with mechanistic data implicating VEGF signaling and cell‑migration pathways. TB‑500 / TB‑4: preclinical work (and reviews) describe effects on actin dynamics, cell migration, angiogenesis and reduced fibrosis; some delivery/scaffold approaches have been evaluated in wound contexts (trial-dd0d1f75c9f563a8; doi-16e6d8ccee8b0df0).

Human evidence

There are no published randomized controlled trials or peer‑reviewed positive clinical outcome reports provided for the three‑peptide blend. For individual components, human evidence is limited and currently mainly registry/early trial activity without posted results: GHK‑Cu has active/registered clinical studies (trial-ccb8a743da81320a / NCT07706361 measuring circulating GHK/GHK‑Cu; trial-f2d77af3b8b5612c / NCT07437586 Phase 2 topical wound healing study) but no results available in the supplied records. BPC‑157 has Phase I/II trials registered (trial-f8d6323ffc71e7ca / NCT02637284; trial-f6808caf91c1c4e4 / NCT07437547) with no posted results in the supplied data. TB‑500 has limited clinical records in the supplied set: one completed small clinical scaffold study using TB4 in a slow‑release sponge (trial-dd0d1f75c9f563a8 / NCT02668055) but no posted results; a clinical trial entry labeled as illustrative/fictional (trial-952d690b40213e68) should not be treated as evidence. A recent review included in the set highlights that translational clinical evidence is lacking and that reliance upon unregulated market use is currently common (doi-16e6d8ccee8b0df0).

Registered trials